Pharmaceutical companies. Russian pharmaceutical manufacturers Production of pharmaceutical products

The largest Russian pharmaceutical companies earned from 15 billion rubles (PJSC Pharmstandard) to 182 billion rubles (JSC NPK Katren) in annual revenue at the end of 2015.

In the last two years, 2015 and 2016, the Russian pharmaceutical industry has shown significant growth - more than 20% in 2016, according to the Minister of Industry and Trade of the Russian Federation Denis Manturov.

At a briefing held at the Russian Ministry of Industry and Trade, Deputy Minister Sergei Tsyb said that the best evidence of the growth of the domestic pharmaceutical industry is that the American pharmaceutical giants are outraged: it is difficult for them to break into the Russian market, since they are being squeezed out by large pharmaceutical companies in Russia. We analyzed and prepared the Top 7 largest Russian pharmaceutical holdings by revenue for 2015.

Pharmstandard

Legal address: Moscow

Registration date: 1996

Founders: Minin Alexander Nikolaevich, Kuznetsov Igor Gennadievich.

CEO: Kuznetsov Igor Gennadievich

  • Authorized capital: RUB 1,000,012.86.
  • Fixed assets: 153,955 thousand rubles
  • Revenue: 21,191,811
  • Accounts receivable: 2,667,522 thousand rubles
  • Accounts payable: 6,961,274 thousand rubles.
  • Net profit: 1,042,833 thousand rubles
  • Net assets: 2,646,595 thousand rubles
  • INN - 7731241639

https://www.euro-service.ru/

Sia International

Joint Stock Company "Sia International LTD" is engaged in the sale of medicines and medical products to pharmacies and medical institutions.

It has warehouse complexes in Moscow and more than 35 cities of Russia. Their total area is more than 200 thousand square meters.

Legal address: Moscow city

Registration date: 1995

Founders: JSC "Rink", Rudinsky Igor Feliksovich.

CEO: Demkin Alexander Yurievich

  • Authorized capital: 20,000,000 rubles
  • Fixed assets: 5,624,687 thousand rubles.
  • Revenue: 59,438,184 thousand rubles
  • Accounts receivable: 13,597,841 thousand rubles.
  • Accounts payable: 20,209,002 thousand rubles.
  • Net profit: -3,111,114 thousand rubles
  • Net assets: 2,908,224 thousand rubles
  • TIN - 7714030099

Sources: official website: https://mpharma.ru/, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

R-Pharm

Joint Stock Company "R-Pharm" specializes in high-tech medicines. Currently, the company is working towards large-scale investment projects.

It is creating a production base as part of the state strategy for the development of the Russian pharmaceutical industry until 2020.

Legal address: Moscow

Registration date: year 2001

Founders: Repik Alexey Evgenievich

CEO: Ignatiev Vasily Gennadievich

  • Authorized capital: RUB 28,400.
  • Fixed assets: 2,119,636 thousand rubles
  • Revenue: 62,204,014 thousand rubles
  • Accounts receivable: 13,435,674 thousand rubles.
  • Accounts payable: 30,682,362 thousand rubles
  • Net profit: 8,608,010 thousand rubles.
  • Net assets: 24,205,818 thousand rubles
  • INN - 7726311464

Sources of information: official website: http://r-pharm.com, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Growth

Closed joint stock company "Rosta". In total, the Rosta pharmaceutical group includes 4 companies: Rosta (engaged in the distribution of medicines), Rosta Marketing (trade marketing), Raduga Production (a plant for the production of solid medicines), United Pharmacy Chain, which includes the companies “Rainbow”, “First Aid”, “Ladushka”.

Legal address: Moscow region, city of Podolsk

Registration date: 2002

Founders: Joint-stock company PJSC "Tampo", Mikhail Mikhailovich Mirilashvili, David Isaakovich Panikashvili, Oleg Yakovlevich Tseytlin, Vadim Valentinovich Strepetov, Boris Albertovich Shepel, Alexander Vasilievich Semenyuk, Oleg Yurievich Konev.

The president: Panikashvili David Isaakovich

  • Authorized capital: 1,000,000 rubles
  • Fixed assets: 621,356 thousand rubles
  • Revenue:63,384,563 thousand rubles
  • Accounts receivable: 18,293,282 thousand rubles.
  • Accounts payable: 35,244,901 thousand rubles
  • Net profit: 415,314 thousand rubles
  • Net assets: 1,755,002 thousand rubles.
  • INN - 7726320638

Sources: official website: rostagroup.ru, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Protek

Closed joint stock company firm "Implementation Center "Protek". The Protek group of companies is engaged in the production, distribution and retail sale of medicines through pharmacy chains.

The holding's production and technological capacities comply with GMP standards.

Legal address: Moscow

Registration date: 1994

Founders: JSC "Protek"

CEO: Pogrebinsky Dmitry Borisovich

  • Authorized capital: 40,000,000 rubles
  • Fixed assets: 1,082,865 thousand rubles.
  • Revenue: 166,578,310 thousand rubles
  • Accounts receivable: 32,742,113 thousand rubles.
  • Accounts payable: 69,059,867 thousand rubles
  • Net profit: RUB 5,419,719.
  • Net assets: 8,094,159 rubles
  • INN - 7724053916

Sources of information: official website of the company: http://www.protek-group.ru, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Quatrain

The geography of Katren's work covers 85 constituent entities of the Russian Federation and delivers more than 18 thousand types of pharmaceutical products.

Legal address: city ​​Novosibirsk

Registration date: 1993

Founders: Konobeev Leonid Valentinovich, Spiridonov Vladimir Nikolaevich

CEO: Konobeev Leonid Valentinovich

  • Authorized capital: 1 billion 500 million rubles
  • Fixed assets: 6,752,880 thousand rubles
  • Revenue: 182,301,551 thousand rubles
  • Accounts receivable: 30,155,368 thousand rubles.
  • Accounts payable: 65,656,588 thousand rubles
  • Net profit: 5,790,742 thousand rubles
  • Net assets: 11,103,940 thousand rubles.
  • INN - 5408130693

Sources: official website: http://katren.ru, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

JSC "VERTEX"(Saint Petersburg)
Production of finished dosage forms and parapharmaceuticals. The company's product portfolio includes more than 200 items. In 2015, a new production site was opened with a design capacity of more than 100 million packages per year.

JSC "Biocad"(St. Petersburg, Moscow region)
Production of drugs for the treatment of infectious, viral, autoimmune and oncological diseases. Production sites are located in St. Petersburg and the Moscow region. The product portfolio includes 45 items.

Group of companies "GEROPHARM"(St. Petersburg, Moscow region)
Production of biotechnological drugs based on genetic engineering technologies, including insulin analogues, as well as other drugs for the treatment of socially significant diseases. The product portfolio includes 10 drugs.

LLC "NTFF "POLYSAN"(Saint Petersburg)
Development and implementation of own-produced drugs into medical practice. The company produces original drugs: Cycloferon, Reamberin, Cytoflavin and Remaxol.

Novartis Neva LLC(Saint Petersburg)
The first plant of the Novartis group of companies in Russia. The planned production capacity is 1.5 billion units of solid dosage forms per year.

Grotex LLC (Solopharm)(Saint Petersburg)
Specialization in the production of liquid sterile dosage forms. The Solopharm plant was put into operation in 2013. The design capacity is more than 1 billion units of products per year.

JSC "Active Component"(Saint Petersburg)
Production of active pharmaceutical ingredients. More than 30 types of API.

LLC "NPF "KEM"(Saint Petersburg)
Industrial chemical synthesis of drug substances. Substances: Dioxidin, Diazolin, Arbidol, Meldonium, Pantogam, Proxadolol, etc.

SKTB "Technolog"(Saint Petersburg)
Production of TOC products, composite materials and devices, medicinal substances, polymer compositions

PJSC "Pharmsintez"(Saint Petersburg)
Production of fine organic synthesis products (TOS) and active pharmaceutical ingredients (API).

Pharmamed LLC(Saint Petersburg)
Release of FPP (Nitroglycerin, Valemidin); Production of active pharmaceutical ingredients (unithiol, iodantipyrine, ethylmethylhydroxypyridine succinate, etc.)

Pik-Pharma Group of Companies(St. Petersburg-Belgorod)
Production of substances and finished medicines. The company has three production sites. The product portfolio includes 13 drugs.

MBNPK "Cytomed"(St. Petersburg-Finland)
Production of peptide drugs. Production sites in St. Petersburg and Lappenranta.

OJSC "Pharmaceutical Factory of St. Petersburg" (St. Petersburg)
Development, production and sale of medicinal products from herbal raw materials

LLC "Samson-Med"(Saint Petersburg)
Production is carried out in the following areas: injection forms; infusion solutions; natural hormonal and enzyme preparations.

CJSC "Northern Star"(Len. region, Kuzmolovsky village)
Production of solid dosage forms: tablets and film-coated tablets, hard gelatin capsules. The assortment portfolio consists of about 40 items.

CJSC "Pharmproekt"(Saint Petersburg)
Production of finished medicines.

Alkor Bio LLC(Saint Petersburg)
Development, production and sale of enzyme immunoassay kits

Pharmacor Production LLC(Saint Petersburg)
Production of a wide range of medicines, dietary supplements, as well as packaging production of drugs from leading European companies.

JSC "Medpolymer"(Saint Petersburg)
Production of medicines, medical devices and dental products.

LLC "Biotech"(Saint Petersburg)
Isolation and purification of recombinant human interleukin-2

OJSC "Pharmstandard"(Moscow)
The company produces more than 200 types of finished medicines. The largest domestic holding

FSUE NPO Microgen, Ministry of Health of the Russian Federation(Moscow)
Development and production of immunobiological, diagnostic and medicinal products

OJSC "Veropharm"(Moscow)
Production of generics, oncology drugs, medical patches.

NPO "PETROVAX PHARM"(Moscow)
Production of original drugs Polyoxidonium, Longidaza, Grippol.

CJSC PharmFirma Sotex(Moscow)
The company's product portfolio includes 67 medicines, including 28 of its own.

OJSC "Valenta Pharmaceuticals"(Moscow region)
Production of solid dosage forms, as well as production of neurological and antimicrobial drugs

LLC "KRKA-RUS"(Moscow region, Istra)
Production of drugs for the treatment of cardiovascular diseases.

JSC "Akrikhin"(Moscow)
GLS production, the company produces about 150 types of drugs

LLC "Alkoy"(Moscow)
Development and production of homeopathic medicines, medicinal cosmetics and dietary supplements

CJSC "Partner"(Moscow)
Development and production of immunobiological drugs, dietary supplements and food products for the treatment of dysbacteriosis

CJSC "Moscow Pharmaceutical Factory"(Moscow)
Production of tinctures, extracts, ointments, syrups, homeopathic preparations, medicinal alcohols...

OJSC "Moskhimfarmpreparaty named after N.A. Semashko"(Moscow)
Production of drugs of various pharmacotherapeutic groups, release of pharmaceutical drugs.

JSC "EKOlab"(Moscow region, Elektrogorsk)
Production of enzyme immunoassay test systems and other diagnostic MIBPs, kits for biochemical, hematological, histological and general clinical laboratory tests, as well as drug products.

OJSC "Nizhpharm"(Nizhny Novgorod)
Part of the STADA CIS holding. Production is located on almost 11.5 thousand square meters. meters with workshops for the production of ointments, creams, suppositories, liniments, tablets.

OJSC "Tatkhimfarmpreparaty"(Kazan)
It has two modern plants: a chemical-pharmaceutical plant and a plant for suture-surgical materials. It has production facilities that allow it to annually produce more than 111 types of finished medicines.

OJSC Kurgan "Sintez"(Mound)
Production of natural and semi-synthetic antibiotic substances, production of pharmaceutical drugs and honey. plastic products.

JSC "Evalar"(Altai region, Biysk)
Development and production of natural medicines and parapharmaceuticals

CJSC "Altaivitamins"(Altai region, Biysk)
A major manufacturer of medicines, natural-based dietary supplements, fortified food products and cosmeceuticals

JSC "Biosintez"(Penza)
Production of various pharmaceutical products

OJSC "Novosibkhimpharm"(Novosibirsk)
Specializes in the production of injection solutions in ampoules and patches.

LLC NPO "SibEnzim"(Novosibirsk)
Production and sale of nucleic acid metabolic enzymes and related drugs.

JSC "Biokhimik"(Saransk)
Produces more than 60 types of drugs: antibiotics, antitumor agents, plasma replacement solutions, diuretics, drugs used for anesthesia, painkillers

OJSC "Kraspharma"(Krasnoyarsk)
Main products: antibiotics, infusions and blood plasma substitutes

JSC "Organika"(Novokuznetsk)
Release of FPP. The main products are drugs acting on the central nervous system.

JSC "Pharmasintez"(Irkutsk)
The country's largest domestic manufacturer of anti-tuberculosis drugs. Among the top twenty pharmaceutical enterprises in Russia in terms of production volumes

Without exaggeration, we can say that providing citizens with medicines and drugs is an important component of the national security of the state. And pharmaceutical production is the most important socially significant sector of the economy.

Government support

Today, the social importance of products such as pharmaceuticals, the production of which is established in our country, has reached such a level that the government is forced to pay serious attention to projects involving the development of this industry. It should be noted that in recent years a number of policy documents have been adopted that promote the organization and development of production, including pharmaceutical substances, but the situation in this area still does not inspire optimism, and here’s why.

Important Industry Features

Pharmaceutical production has its own characteristics. They are presented:

  • high technology-intensive products;
  • the significant duration of the development process of new medicinal components, as well as corresponding drugs;
  • long life cycle of drugs, including all stages - development, production and sales of products;
  • the nature and duration of the production cycle required for the production of finished products;
  • a wide variety of types of technological processes that are used in such areas as the production of pharmaceutical substances;
  • a wide variety of types of raw materials and supplies, as well as equipment used in the production cycle;
  • multi-stage technological processes.

Investment

From the point of view of a potential investor, pharmaceutical production has a number of distinctive features. And the main negative points that are worth paying attention to are:

  1. Higher investment attractiveness of the production of finished products, that is, medicines, in comparison with the production of medicinal substances. This trend was formed under the influence of modern economic conditions. An explanation for this fact can be the high material and energy intensity of the production of standardized semi-finished products, which led to a decrease in the profitability of their production, and sometimes to the unprofitability of such production.
  2. The recent increase in the cost of material resources has caused a significant increase in the cost of substances produced in our country. The consequence of this is that they are affected to a level that exceeds the world level. Such trends have led to the fact that pharmaceutical production has become unable to offer competitive products.
  3. Providing foreign manufacturers with easy access to the pharmaceutical market of our country. This has created enormous competition for every domestic manufacturer, which in most cases is unable to resist the active expansion of inexpensive substances of low quality into the domestic market.

Main trends in the pharmaceutical market

According to some estimates, the volume of the pharmaceutical market in our country in recent years reaches 1 trillion rubles. At the same time, domestic medicines in the total volume of sold products of this type account for only about 25% in monetary terms and approximately 60% in physical terms.

Hot issues

Today, one of the most pressing issues that concerns those interested in the development of domestic pharmaceutical production is the origin of standardized semi-finished products, which are the basis for the production of finished medicinal products in our state. Unfortunately, the experts’ conclusions do not inspire optimism among domestic producers. Pharmaceutical production of medicinal components is practically undeveloped in our country.

Import of pharmaceutical substances

As for imports, in recent years a situation has arisen where about 80% of the volume of imported pharmaceutical substances in monetary terms is occupied by Germany, France, Italy and China.

It is noteworthy that when considering the physical expression of import volumes, completely different figures are obtained. Thus, its largest share today is China - more than 70% of the total volume. Considering the ratio of specific shares calculated by natural and cost indicators, we can come to the conclusion that substances produced in the named country are characterized by a significantly lower price in comparison with similar products from other countries.

What is imported

Imports include mainly components of very long-known drugs, represented by acetylsalicylic acid, paracetamol, metamizole sodium, metformin, ascorbic acid and others, which are in demand among the population mainly due to their low cost.

It says that the share of what is produced at domestic enterprises is characterized by a negligible figure, 8-9% of the total volume of the pharmaceutical products market.

conclusions

Probably, the above facts allow us to state the obvious need to restore the production volumes of the products in question. The technology for pharmaceutical production of substances must be restored and applied in full. The development of this area is necessary, first of all, in order to ensure the national security of the state.

Such statements are not empty words at all. Many manufacturers are faced with the fact of providing the domestic economy with substances from foreign suppliers on a residual basis. And this cannot but cause concern.

Read about the project

When you buy a product or service from someone, you give him money for development, finance him (help). If you don’t buy, you don’t help (don’t finance). By buying Russian goods and services, you help Russian people. This is reasonable for you if you are part of the Russian people.

Dmitry Mezentsev

Subscribe to RUSSIANSOYUZRF @russkii_souz

The information you add must meet our selection criteria

  • Russian manufacturers- these are Russian production owners who produce goods on the territory of their country, registered in it and using the labor of Russian workers. Accordingly, they produce Russian goods.
  • Russian owners or co-owners of production, using anything foreign in the production process (companions, workers, territory, etc.) are placed in the section “Production with Russian participation" Accordingly, they produce goods with Russian participation.
  • Russian sellers- these are Russian entrepreneurs who use the labor of Russian workers and sell Russian goods or goods with Russian participation. If the store has at least one shelf with Russian goods, then the store can be placed in the catalog and advertise these goods.
  • Russian services provided by Russian entrepreneurs who use the labor of Russian workers and strive, if possible, to use Russian goods.

Also be sure to check out